Biologic therapies for chronic obstructive pulmonary disease

Area of Science:

• Pulmonary Medicine
• Immunology
• Pharmacology

Background:

• Chronic obstructive pulmonary disease (COPD) involves complex inflammation resistant to corticosteroids.
• There is a significant unmet need for novel anti-inflammatory treatments for COPD.
• Monoclonal antibodies (mAbs) targeting inflammatory mediators are a potential therapeutic avenue.

Approach:

• This review examines the therapeutic potential of monoclonal antibodies (mAbs) in COPD management.
• The focus is on mAbs designed to inhibit cytokines, chemokines, or their receptors.

Key Points:

• Currently, no mAb targeting cytokines or chemokines has demonstrated significant therapeutic benefit in general COPD populations.
• Monoclonal antibodies targeting the IL-5 pathway show a statistically significant, though modest, effect in COPD patients with eosinophilic phenotypes.
• The complexity and diverse endotypes of COPD may explain the limited efficacy of single-target mAbs.

Conclusions:

• Monoclonal antibody therapy for COPD is challenging due to the multifaceted nature of the disease.
• Targeting specific cytokines or chemokines may require evaluation within well-defined, focused patient populations based on COPD endotypes.
• Future therapeutic strategies may involve personalized approaches for COPD treatment.